Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Fig. 1

The basic characteristics of YM101. a The structure of YM101. YM101 contains two anti-PD-L1 regions and two anti-TGF-β regions. The Fc region of YM101 is an IgG1/IgG2 hybrid fragment: the CH2 is from IgG2, and the CH3 is from IgG1. b The results of non-reduced and reduced SDS-PAGE assays. A single band was observed in the lane of non-reduced YM101, and two bands were found in the lane of reduced YM101. c The results of non-reduced and reduced CE-SDS assays. In non-reduced CE-SDS, one peak was detected. In reduced CE-SDS, two peaks were detected (one for short chain and the other for long chain). The purity of YM101 is over 99%. d The binding of YM101 to PD-L1. Serially diluted YM101 or controls were incubated with plate-coated PD-L1. The binding affinity was measured by anti-hIgG ELISA. eg The binding of YM101 to TGF-β. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. The binding affinity was measured by anti-hIgG ELISA. hj The simultaneous binding to TGF-β and PD-L1. Serially diluted YM101 or controls were incubated with plate-coated TGF-β1, TGF-β2, and TGF-β3. Then, PD-L1-Biotin and peroxidase-conjugated streptavidin were used for ELISA assays. α-TGF-β: anti-TGF-β, α-PD-L1: anti-PD-L1

Back to article page